Ocera Therapeutics Reports Third Quarter 2015 Financial Results
04 nov. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
STOP-HE Reaches 50% Enrollment; Expected Completion H2 2016 6 Accepted Abstracts at The Liver Meeting® 2015 Underscore the Potential Breadth of Therapeutic Application for OCR-002 ...
Ocera to Present at BIO Investor Forum 2015
13 oct. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
05 oct. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy
16 sept. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
01 sept. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Therapeutics Reports Second Quarter 2015 Financial Results
03 août 2015 16h13 HE
|
Ocera Therapeutics, Inc.
Continued Strong Enrollment in STOP-HE On Track for Initiation of Phase 1 Trial with Oral Formulation of OCR-002 in Third Quarter $20 Million Debt Facility Extends Cash Resources to Mid-2017 PALO...
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and Silicon Valley Bank
30 juil. 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Therapeutics to Present at the JMP Securities Life Sciences Conference
16 juin 2015 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference
29 mai 2015 13h30 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera CEO to be Honored at the 17th Annual American Liver Foundation's Salute to Excellence Awards Gala in San Francisco
04 mai 2015 08h35 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...